Does semaglutide's patent extension claim hold up to scrutiny?

What did @drzainhasan1 actually say?

Dr. Hasan claims Eli Lilly is lobbying to have retatrutide classified as a biologic rather than a small-molecule drug or peptide, specifically by pushing to have it counted as having 40 amino acids instead of 39. His argument: if it clears the 40-amino-acid threshold, it becomes a biologic, compounding pharmacies lose access to it, and Eli Lilly locks in a much longer patent runway, similar to what happened with HCG and FSH.

He also calls retatrutide a "miracle drug" producing "30% weight loss in about a year" with "not so bad side effects," and frames the classification push as a deliberate rule-bending strategy to protect market exclusivity for "30 to 40 years."

That is a lot of specific claims packed into a short video. Some of them are directionally correct. Some are garbled in ways that matter.

Does the science back this up?

The weight loss figure is real, but it comes from early-phase data, not a completed trial. The classification argument has real legal stakes, but the mechanism Dr. Hasan describes is not quite how it works.

Phase 2 trial data published by Jastreboff et al. (2023, New England Journal of Medicine) showed that retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, produced up to 24.2% mean body weight reduction over 48 weeks in adults with obesity. The "30% weight loss" figure Dr. Hasan cites is on the high end of what was observed in a subset of participants at the highest dose, so it is not fabricated, but it is also not the average outcome, and phase 2 data does not equal real-world performance.

On the biologic question: the FDA's statutory threshold under the Public Health Service Act does define a "protein" as a polymer of 40 or more amino acids. Retatrutide, at 39 amino acids, sits just below that line. This is a real and consequential regulatory boundary, not something Dr. Hasan invented.

What did they get wrong (or right)?

Credit where it is due: the 39-versus-40 amino acid threshold is real, the compounding pharmacy implication is real, and the HCG/FSH comparison is a reasonable analogy. The FDA has previously blocked compounding of biologic drugs, and that precedent shapes what is at stake here.

But there are meaningful errors. First, Dr. Hasan implies Eli Lilly can somehow reclassify retatrutide's amino acid count, as if the company can just add an amino acid to a finished molecule for regulatory purposes. That is not how drug classification works. The classification follows the molecular structure of the drug itself. If Eli Lilly wanted to pursue biologic status, it would require developing a structurally different compound, which would functionally be a new drug.

Second, the "30 to 40 years" patent protection claim is significantly overstated. Standard small-molecule drug patents run 20 years from filing, with exclusivity extensions that rarely push effective market exclusivity beyond 12 to 14 years. Biologics do get additional protections, including 12 years of exclusivity under the Biologics Price Competition and Innovation Act, but "30 to 40 years" is not a number grounded in pharmaceutical patent law.

Third, describing retatrutide as a "miracle drug" in a health context is the kind of framing that erodes trust when the drug eventually shows real-world limitations, which all drugs do.

What should you actually know?

The broader concern Dr. Hasan raises, that pharmaceutical companies use regulatory classification strategically to limit competition, is legitimate and well-documented. Evergreening strategies, which involve reformulating or reclassifying drugs to extend exclusivity, are a recognized industry practice. The 40-amino-acid threshold is a real regulatory seam that creates genuine incentive for companies to pursue biologic classification for borderline compounds.

What is less clear is whether Eli Lilly is actively lobbying to reclassify retatrutide specifically. As of the latest available public information, retatrutide is still in Phase 3 trials. No public FDA filing or lobbying disclosure reviewed here confirms the specific campaign Dr. Hasan describes. That does not mean it is not happening, it means this video presents a plausible hypothesis as confirmed fact.

For patients and consumers, the practical implication is straightforward: if retatrutide reaches market and receives biologic classification, compounding access will almost certainly be restricted. That would affect cost and accessibility significantly. It is worth watching, but not worth treating a TikTok video as the final word on active regulatory proceedings.